See more : Halozyme Therapeutics, Inc. (HALO) Income Statement Analysis – Financial Results
Complete financial analysis of Twist Bioscience Corporation (TWST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Twist Bioscience Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- GDEX Berhad (0078.KL) Income Statement Analysis – Financial Results
- Addnode Group AB (publ) (0GMG.L) Income Statement Analysis – Financial Results
- Genetec Corporation (4492.T) Income Statement Analysis – Financial Results
- The Hydration Pharmaceuticals Company Limited (HPC.AX) Income Statement Analysis – Financial Results
- Ping An Healthcare and Technology Company Limited (1833.HK) Income Statement Analysis – Financial Results
Twist Bioscience Corporation (TWST)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.twistbioscience.com
About Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 312.97M | 245.11M | 203.57M | 132.33M | 90.10M | 54.39M | 25.43M | 10.77M | 2.27M |
Cost of Revenue | 179.63M | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M | 32.19M | 24.02M | 9.42M |
Gross Profit | 133.35M | 89.73M | 84.24M | 51.71M | 28.69M | 6.96M | -6.76M | -13.25M | -7.15M |
Gross Profit Ratio | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.80% | -26.59% | -123.09% | -315.20% |
Research & Development | 90.85M | 106.89M | 120.31M | 69.07M | 43.01M | 35.68M | 20.35M | 19.17M | 18.23M |
General & Administrative | 0.00 | 186.84M | 210.55M | 133.40M | 102.07M | 78.83M | 42.55M | 25.96M | 18.07M |
Selling & Marketing | 0.00 | 2.90M | 2.40M | 2.50M | 1.20M | 1.30M | 900.00K | 100.00K | 200.00K |
SG&A | 218.40M | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M | 43.45M | 26.06M | 18.27M |
Other Expenses | 44.93M | 10.26M | -1.09M | -1.37M | -182.00K | -265.00K | -121.00K | -55.00K | 73.00K |
Operating Expenses | 354.18M | 306.89M | 333.26M | 204.97M | 146.27M | 115.81M | 63.80M | 45.23M | 36.50M |
Cost & Expenses | 533.81M | 462.27M | 452.59M | 285.59M | 207.68M | 163.24M | 95.99M | 69.25M | 45.93M |
Interest Income | 15.34M | 14.37M | 3.06M | 435.00K | 1.50M | 3.03M | 999.00K | 412.00K | 241.00K |
Interest Expense | 29.00K | 5.00K | 80.00K | 367.00K | 787.00K | 1.29M | 1.31M | 905.00K | 746.00K |
Depreciation & Amortization | 31.43M | 29.31M | 36.64M | 11.99M | 6.68M | 6.31M | 5.73M | 5.02M | 4.23M |
EBITDA | -176.71M | -174.15M | -191.55M | -143.91M | -132.09M | -99.77M | -63.95M | -53.10M | -39.11M |
EBITDA Ratio | -56.46% | -71.05% | -121.36% | -116.52% | -129.04% | -195.06% | -251.52% | -493.21% | -1,723.80% |
Operating Income | -220.83M | -217.16M | -249.02M | -153.26M | -117.58M | -108.85M | -70.56M | -58.48M | -43.66M |
Operating Income Ratio | -70.56% | -88.60% | -122.33% | -115.81% | -130.50% | -200.15% | -277.50% | -543.16% | -1,924.02% |
Total Other Income/Expenses | 12.67M | 13.69M | 6.50M | -1.30M | 530.00K | 1.47M | -435.00K | -548.00K | -432.00K |
Income Before Tax | -208.17M | -203.47M | -228.27M | -154.03M | -139.55M | -107.38M | -70.99M | -59.03M | -44.09M |
Income Before Tax Ratio | -66.51% | -83.01% | -112.14% | -116.39% | -154.88% | -197.44% | -279.21% | -548.25% | -1,943.06% |
Income Tax Expense | 560.00K | 1.15M | -10.41M | -1.93M | 382.00K | 292.00K | 242.00K | 280.00K | 819.00K |
Net Income | -208.73M | -204.62M | -217.86M | -152.10M | -139.93M | -107.67M | -71.24M | -59.31M | -44.09M |
Net Income Ratio | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% | -550.85% | -1,943.06% |
EPS | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
EPS Diluted | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
Weighted Avg Shares Out | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
Weighted Avg Shares Out (Dil) | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
The 3 Best Med Tech Stocks to Buy Now
Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience Reports Fiscal Third Quarter 2024 Financial Results
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024
Source: https://incomestatements.info
Category: Stock Reports